| 证券代码 | NITE.O |
| 证券名称 | Nightstar Therapeutics plc ADR |
| 证券类型 | 美国存托凭证 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-09-28 |
| 首发价格(元) | 14 USD |
| 首发数量(股) | 5360000 |
| 首发募资额(元) | 75,040,000.00 USD |
| 首发主承销商 | BMO Capital Markets Corp,Jefferies LLC,Leerink Partners LLC |
| 货币单位 | USD |
| 公司名称 | Nightstar Therapeutics plc |
| 注册地址 | 英格兰和威尔士 |
| 办公地址 | 215 Euston Road, London, United Kingdom |
| 成立日期 | 2017-07 |
| 董事会主席 | Chris Hollowood |
| 公司属地 | United Kingdom 英国 |
| 公司网址 | www.nightstartx.com |
| 电话 | +44 (20) 7611-2077 |
| 传真 | - |
| 公司简介 | Nightstar Therapeutics plc is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Leveraging its expertise in ophthalmology, gene therapy and drug development, the company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases for which there are no currently approved treatments. |